This report updates the risk assessment by Crump and Allen for benzene-induced leukemia that was based on a cohort exposed to benzene in the manufacture of Pliofilm. The present study derives new risk estimates using data from follow-up through 1987 
Introduction
Crump and Allen (1) developed estimates of the benzene-related risk of leukemia using data from a cohort of workers exposed to benzene during the manufacture of Pliofilm, a glossy membrane made from rubber hydrochloride and used chiefly for packaging and other water-resistant materials (2) (3) (4) (5) . This risk assessment was used by the U.S. Occupational Safety and Health Administration (6) to support a reduction of the permissible exposure limit (PEL) for benzene from 10 ppm to 1 ppm; it also formed the basis for the "unit risk estimate" for inhaled benzene developed by the U.S. Environmental Protection Agency (7) .
Since the Crump and Allen risk assessment (1), significant new information has become available on the Pliofilm cohort. First, follow-up of the cohort has been extended by the (8) . Crump (9) presents a more detailed description of this work.
Methods
The present analysis used mortality data from follow-up by NIOSH of a cohort of 1717 white male workers employed in Pliofilm operations for at least 1 day at either the St. Marys or the Akron, Ohio manufacturing facility (6) . The total included 577 workers in jobs not considered by Rinsky et al. (3, 4) to involve benzene exposure [although both Crump and Allen (1) and Paustenbach et al. (8) estimated some exposure to benzene in these jobs] and for whom follow-up did not extend beyond 31 December 1981. The mortality experience of the 1140 remaining workers was followed through 31 December 1987. Paxton et al. (5) provided a detailed description of the status of the cohort through the most recent follow-up.
The analysis focuses upon lymphatic and hematopoietic cancer (International Classification ofDiseases, 9th Revision, codes 202-209), all leukemias, and a category of acute leukemia defined as acute myelogenous or acute monocytic leukemia (AMML). AMML includes all of the acute nonlymphocytic leukemias that have been identified in the Pliofilm cohort. A lifetable analysis is conducted for all three cancer categories and, based on the results of the lifetable analysis, dose-response modeling is conducted for all leukemias and for AMML. The type of leukemia is not known for 2 of the 14 cases found in the most recent follow-up, and these cases were excluded from the dose-response modeling ofAMML.
Following the approach used by Crump and Allen (1), both absolute risk and cumulative risk models were used. An additive risk model assumes that benzene increases the background mortality rate by an additive amount that depends on prior benzene exposure; a multiplicative risk model assumes that benzene increases the background mortality rate by a multiplicative factor that depends on prior benzene exposure. Both linear and nonlinear versions of each of these models were considered. For the linear additive risk model, the mortality rate at age t for the cancer of interest is assumed to be in the form The study also involved analyses that incorporated a parameter that multiplied a(t) to account for the possibility that the background mortality rates in the Pliofilm cohort differed systematically from total U.S. rates (9) . However, there was no evidence that U.S. rates were not appropriate, and those analyses are not discussed here.
The summary exposure measure, X(t), discussed in the present report, is cumulative exposure (ppm-years/m3) to age t, with a 5-year lag (i.e., omitting exposures during the 5 most recent years). Lags of 0 and 3 years were also considered, but they did not describe the data as well as a lag of 5 years.
We also considered a form of weighted exposure that was based on the leukemiaresponse pattern observed following X-ray treatment (10) . With weighted exposure, the impact of benzene exposure occurring during a small time slice on future cancer mortality increases with increasing elapsed time from zero impact to a maximum level of impact and decreases thereafter. The effect of the complete pattern of benzene exposure is obtained by integrating the effects of exposures during each time slice. In general, weighted exposure did not describe the mortality data as well as cumulative exposure and it produced risk estimates roughly comparable to those obtained using cumulative exposure. Estimates of lifetime risk based on weighted exposure could be either higher or lower than those based on cumulative exposure, but generally the differences were less than a factor of 2 (9) . Only results based on cumulative exposure are presented here.
To investigate the possibility of a nonlinear relationship between benzene exposure and mortality rate, the linear models described above were expanded to include nonlinear terms. Two types of nonlinearity were considered. In nonlinearity that was dependent on the area under exposureduration curve (AUC), additional terms were incorporated that varied as the square or cube of cumulative exposure. That is, AUC-dependent, nonlinear models were defined by replacing PX(t) in the linear additive and multiplicative models by X(t) + 532X2(t) + 13X3(t). Intensitydependent nonlinear models were described the same way except that cumulative exposure raised to a power, X'(t), was replaced by Xi(t) = I5x'(v)dv where x(v) is the intensity of exposure (ppm) at age v (i.e., Xi(t) is the accumulation [integral] of instantaneous exposure raised to the ith power, where i = 2 or i = 3). With intensity-dependent nonlinearity, the intensity of exposure was given greater weight than the duration of exposure. For example, at the completion of the exposure period, X2(t) = 100 (ppm-years)2 both for exposure to 100 ppm for 1 year and exposure to 10 ppm for 10 years.
However, X,2(t) = 10,000 ppm2-years for the former exposure pattern and 1000 ppm -years for the latter pattern, which represents a 10-fold difference. Intensitydependent nonlinearity may be more appropriate than AUC-dependent nonlinearity for modeling biological effects brought about by acute toxicity.
Analyses were performed using both the The method of maximum likelihood was used to fit models to data and to test hypotheses. Estimates of the potency parameters (,B and 3i) were translated into estimates of the additional lifetime risk of cancer from specific patterns of benzene exposure (lifetime occupational exposure and continuous lifetime exposure) using a formula for the lifetime probability of cancer based on United States mortality rates (males and females combined) for total mortality and for the cancer of interest. In converting from occupational exposure to continuous exposure, it was assumed that Pliofilm workers were exposed for 8 hr/day, 250 days/year, and breathed 10 m3 of air per 8-hr workday. It was further assumed that persons exposed continuously breathe 20 m3 of air per 24-hr day. Additional details regarding methods of analysis are provided in Crump (9).
Results Table 1 contains a list of the 21 cases of lymphatic and hematopoietic cancer in the cohort along with the cumulative benzene exposures (zero lag) at time of death computed using both the Paustenbach et al. and the Crump and Allen exposure matrices. This table also indicates which of these 21 cases were AMML (8-10 cases) or leukemia of any type (14 cases). All the model fits for AMML included only the eight confirmed cases and omitted the two questionable cases. Both questionable cases involved relatively low exposures to benzene. Table 2 presents the results of the lifetable analysis of the association of various categories of hematopoietic cancer, with cumulative exposure defined using the Paustenbach et al. exposure matrix. A similar analysis (not shown) based on the Crump and Allen exposure matrix gave comparable results. A dose response was observed for each of the three categories, AMML, all leukemias, and total lymphatic and hematopoietic cancer. However, neither the dose response for all leukemias nor that for total lymphatic and hematopoietic cancer was as strong as that for AMML; and a dose response was not apparent for either of these categories if AMML was excluded. For the category defined as total lymphatic and hematopoietic cancer excluding leukemia, there was a slight deficit of cancer deaths (observed = 7, expected = 7.3), and there was no indication of a dose response (other than a single case in the high-exposure group). There was a nonsignificant excess for non-AMML leukemias [expected = 3. 1, observed = 4 (p= 0.38) to 6 (p=0.10)]. However, all of the non-AMML leukemias were associated with exposures < 400 ppmyears, whereas five of the AMMLs were associated with exposures > 1000 ppmyears (only 0.06 expected). Thus, AMML was the only response clearly related to benzene exposure. Consequently, results based on the multiplicative risk models will be emphasized in the remainder of the paper. Using this combination, the best-fitting models were quadratic for both AMML and all leukemias. Although standard errors are not provided in Table 4 , the fact that both of these p-values are slightly greater than 0.05 implies that the 95% upper confidence limits on the linear term in these nonlinear models will be slightly greater than the potency estimates derived from the linear versions of these fits (Table 3) . (8) produces a purely quadratic dose response, whereas the Crump and Allen exposure matrix (1) produces an essentially linear dose response. Table 6 contains estimates of the number of additional deaths per 1 million persons 
Discussion
The two exposure matrices lead to quite different conclusions concerning the shape of the dose response. Whereas dose responses were essentially linear when the Crump and Allen (1) exposure matrix was used, there was evidence of intensity-dependent nonlinearity in dose responses derived using the Paustenbach et al. exposure matrix (Table  4) ; based on this matrix, each of the three best-fitting models was quadratic, and departures from linearity were borderline significant in each case. Estimates of risk from 45 years of exposure at 1 ppm based on these quadratic models were about 100-fold smaller than corresponding estimates derived from linear models.
The Paustenbach et al. (8) exposure matrix was based on a much more detailed investigation than that conducted by Crump and Allen (1). Based on review of their work and personal knowledge of methods used by Crump and Allen, we believe that the Paustenbach et al. matrix is likely to provide a better representation of exposures in the cohort. Nevertheless, considerable uncertainty exists with regard to exposures during the earliest period of plant operation. Paxton et al. (5) showed that the average exposure in the cohort based on the Paustenbach et al. exposure matrix was about 2-fold higher than that based on the Crump and Allen exposure matrix and about 4-fold higher than that based on the Rinsky et al. (4) exposure matrix also were correlated with blood counts. However, Hornung did not use his method to evaluate the other two exposure matrices.
The large differences in risk obtained in this study between linear and nonlinear models are extremely important to the regulation of benzene. Unfortunately, it is not possible to accurately determine the amount of nonlinearity present in the dose response based on the information available from the Pliofilm cohort. Perhaps continued follow-up of the much larger Chinese cohort (R Hayes, unpublished data) will help further narrow the range of risks associated with human exposure to benzene.
